Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
Medical product company reports financial performance for 4Q and year 2004
February 20th, 2005
In the fourth calendar quarter (4Q) of 2004, Utah Medical Products, Inc. (UTMD) achieved 3% higher earnings per share (eps) compared to the same quarter in the prior year in its regular operations. Fourth quarter 2004 eps were $.39 compared to $.38 in 4Q 2003. Not included in regular eps during 4Q 2004, was $500,000 in extraordinary operating expenses resulting from increasing UTMD's reserve for litigation expenses. The company estimates that this extraordinary expense, added to its preexisting reserve, will be sufficient to cover legal expenses required to complete the litigation process with the U.S. Food & Drug Administration (FDA) through June 2005. ...
Source: Medical Letter on the CDC & FDA (2005-02-20)
|
